Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
Primary Industries
- Drugs
- Cancer
- Therapeutic
- Disease
- DNA
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 279316
under the Licensors licensed Know How, to develop, use, manufacture, have manufactured, import, formulate, package, sell and offer for sale Products in the Field in the Territory.
Licensor grants an exclusive, even as to Licensor right to use in the Territory any trademarks hereafter owned or controlled by Licensor and used or proposed to be used by Licensor in connection with the marketing of the Product in the Field outside of the Territory.
Licensor will disclose and make available all Licensor Know-How and Licensed Know-How, at Licensors expense promptly following the Effective Date.
Product means a pharmaceutical preparation comprised of or containing AQ4N, and any other product or compound the manufacture, use or sale of which either falls within the scope of, or utilizes any method or process which falls within the scope of any Valid Claim or embodies or utilizes any Licensor Know-How or Licensors Licensed Know How.
Interim data from the UK-based Phase 1 dose escalation study of AQ4N in combination with radiation in esophageal cancer was presented at the American Society for Clinical Oncology annual meeting in June 2004 and showed the agent to be well tolerated.
IPSCIO Record ID: 294270
(A) exclusive licences under the Patents to manufacture, have manufactured, use, import, market, have marketed, sell, have sold, or otherwise dispose of Licensed Products in the Field in the Patent Territories; and
(B) a worldwide exclusive Sub-license as between Licensors and Licensee (but with it being acknowledged and agreed that Licensors only has a sole license to the Know-how from Party A under the Party A Agreement and such exclusive sub-license to Licensee is subject to the rights of Party A under the Party A Agreement) for the purposes set out in the agreement to use the Know-How and the copyright in the Know how in the Field.
Patents – (i) the patents and applications for patents specified and any patent which may be granted pursuant to any of such applications; and (ii) any patents and applications corresponding to such patents and applications which may be granted to or made by Licensors in other countries; and (iv) any amendments, reissues, reexaminations or extensions of such patents, any supplementary protection certificates relating to such patents which are granted to Licensors, and any divisions, continuations-in-part and continuations of such applications.
US Patent #5,132,327 – Anti-cancer compounds
US Patent #6,320,063 – Synthetic method
US Patent #7,074,835 – Formulations of anthraquinone derivatives
Licensed Product means
(a) AQ4N; or
(b) any product made or sold or otherwise disposed of, in any country by, or on behalf of, the Licensee or a Sub-licensee or their Affiliates, and which
(i) falls within the scope of, or utilises any method or process which falls within the scope of Valid Claims of any of the Patents; or
(ii) embodies or utilises any of the Know How.
Combination Product means a Licensed Product consisting of AQ4N and at least one other Active Ingredient.
AQ4N AQ4N is a novel, tumor-selective prodrug with potential applicability to multiple tumor types, both in combination with a number of chemotherapeutic agents and as a monotherapy for hematological malignancies.
IPSCIO Record ID: 243433
The patent is for Substituted Indazole Derivatives Active as Kinase Inhibitors.
RXDX-103 is an inhibitor of the cell division cycle 7-related (Cdc7) protein kinase, and RXDX-104 is a program to identify a highly selective inhibitor of the rearranged during transfection (RET) tyrosine kinase. Each of these programs is in preclinical development for the potential treatment of multiple cancers.
Loss of cell cycle control is a hallmark of cancer, and interfering with the DNA replication process is a proven strategy for cancer therapy. Currently available chemotherapies, such as anti-metabolites, topoisomerase inhibitors, and crosslinking and intercalating agents, classically take a broad-based approach to inhibiting the elongation step of DNA replication. This strategy has led to successful treatment outcomes, but off-target effects can lead to dose-limiting toxicity. Cdc7 is a serine/threonine protein kinase essential for the initiation step of DNA replication during the synthesis (S) phase.
Licensee has capabilities in the development of oncology products.
IPSCIO Record ID: 369293
5,874,418 – Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
6,046,177 – Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
6,133,248 – Polar drug of prodrug compositions with extended shelf-life storage and a method of making thereof
Licensed Product means (a) a Compound combined with or formulated using Captisol for ultimate use in humans in a dosage form/formulation, or (b) a pharmaceutical composition that includes a Compound and that is developed with the assistance of or incorporates any then-confidential component of the Captisol Data Package.
Compound means the proprietary Licensee isoflavone-based drug compound known as ME-143 (also known as NV-143) or the proprietary Licensee mitochondrial inhibitor drug compound known as ME-344, or any derivative, homolog, or analog of ME-143 or ME-344 or any isomer, salt, hydrate, solvate, amide, ester, metabolite, or prodrug of any of the foregoing.
Captisol Related Compound means Captisol or any derivative, homolog analog of Captisol or any isomer, salt, hydrate, solvate, amide, ester, metabolite or product of any of the foregoing, including without limitation sulfobutylether g(gamma) cyclodextrin sodium salt.
Licensed Product Family means one or more Licensed Products which are based on the same Compound(s) (or any isomers, salts, hydrates, solvates, amides, esters, metabolites, or prodrugs of the foregoing), irrespective of whether such Licensed Products contain different dosage forms, proportions or formulations of such Compound(s), utilize different inactive ingredients and/or are marketed for different indications. Notwithstanding the foregoing, a Licensed Product based on a Compound shall be deemed to be in a distinct Licensed Product Family from a Licensed Product based on the combination of the same relevant Compound with any other active pharmaceutical ingredient. As such, if Licensee develops one Licensed Product with ME-344 as the sole active ingredient with Captisol and also develops another Licensed Product with ME-344 in combination with another active ingredient with Captisol, then two distinct sets of milestone payments shall be potentially due under this Agreement, one for each of such two distinct Licensed Products.
Captisol is for use with the Licensee’s isoflavone-based drug compounds.
ME-344 is our isoflavone-derived mitochondrial inhibitor drug candidate. In preclinical studies, ME-344 has been shown to cause cell death in multiple human tumor cell lines, including ovarian cancer stem cells, by interfering with mitochondrial energy generation.
Field means the entire field of prevention, diagnosis and treatment of all human and animal diseases and disorders with the exceptions of (i) ocular treatment of any disease or condition with a formulation including a hormone; (ii) topical ocular treatment of inflammatory conditions; (iii) treatment and prophylaxis of fungal infections in humans; and (iv) any ocular treatment for retinal degeneration.
IPSCIO Record ID: 233475
And, for the Exclusive License Grant, Licensor grants an exclusive license to use and exploit the NOS Patent Assets and the Licensors NOS Know-How to develop, make, have made, use, import, offer for sale, market, commercialize, distribute and sell and otherwise dispose of the NOS Inhibitor Technology and any NOS Inhibitor and the Split Dose Patent Assets and the Licensors Split Dose Know-How to develop, make, have made, use, import, offer for sale, market, commercialize, distribute and sell and otherwise dispose of Compound or Product using the Split Dose Technology, each solely in connection with the use of Compound and/or Product in the Territory. The exclusive license granted includes the right to grant sublicenses.
The Product shall mean any product in final form for commercial sale by prescription, over-the-counter, or by any other method, or, where the context so indicates, the product being tested in clinical trials, which contains Compound as at least one of the therapeutically active ingredients, in all final dosage forms and package configurations for any indication, or any line extension thereof.
The Compound shall mean the chemical compounds known as benzimidazole carbamate class vascular targeting agents,including those designated ANG-600 Series, whose more specific chemical names are 5 (6) substituted benzimidazole-2-carbamates, and any derivative, homolog, analog or conjugate of any of the foregoing, and any isomer, salt, hydrate, solvate, metabolite, or prodrug or the like of any of the foregoing.
The NOS Inhibitor shall mean a chemical composition that inhibits the formation or action of nitric oxide, including those disclosed in the NOS Patent Assets.
NOS Inhibitor Technology shall mean technology relating to the combination of vascular targeting agents, including Compound, and an NOS Inhibitor, including the inventions disclosed in the NOS Patent Assets.
NOS Patent Assets shall mean United States and foreign patents and patent applications, which shall be deemed to include certificates of invention and applications for certificates of invention, which as of the Effective Date or at any time during the term of this Agreement
– are owned by Llicensor (including Licensors interest in jointly owned patents and patent applications) or which Licensor through license or otherwise has or acquires rights, and
– relate to the combination with Compound or Product of an NOS Inhibitor or the NOS Inhibitor Technology including but not limited to methods of their manufacture, methods of their use, or otherwise relate to Licensor NOS Know-How, including all certificates of invention, divisions, continuations, continuations-in-part, reissues, supplementary protection certificates or the like of any such patents and current and future patent applications.
Split Dose Patent Assets shall mean United States and foreign patents and patent applications, which shall be deemed to include certificates of invention and applications for certificates of invention, which as of the Effective Date or at any time during the term of this Agreement
– are owned by Licensor including Licensors interest in jointly owned patents and patent applications or which Licensor through license or otherwise has or acquires rights, and
– relate to the use of Compound or Product in divided doses including but not limited to methods of their manufacture, methods of their use, or otherwise relate to Licensor Split Dose Know-How, including all certificates of invention, divisions, continuations, continuations-in-part, reissues, supplementary protection certificates or the like of any such patents and current and future patent applications.
The Split-Dose Technology shall mean a method of administering any vascular damaging agent in a divided dose, including the inventions disclosed in the Split-Dose Patent Assets.
